Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 3, 2006, Pages 385-390

  Shemyakin, Alexey ^a   Böhm, Felix ^a   Wagner, Henrik ^a,b   Efendic, Suad ^a,b   Båvenholm, Peter ^a   Pernow, John ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Endothelin 1; Endothelium; Forearm; Insulin resistance; Nitric oxide; Vasodilatation

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITROPRUSSIDE SODIUM; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; OLIGOPEPTIDE; PIPERIDINE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM; FOREARM; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; BLOOD FLOW; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ENDOTHELIUM, VASCULAR; FOREARM; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; REGIONAL BLOOD FLOW; VASODILATION;

EID: 33745685243     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000210070.47205.16     Document Type: Article

References (30)

1. Egan BM, Greene EL, Goodfriend TL. Insulin resistance and cardiovascular disease. Am J Hypertens. 2001;14:116S-125S.
2. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol. 1999;84:11J-14J.
3. Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708-723.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
5. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
6. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.
7. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med. 2000;247:425-431.
8. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391-415.
9. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999;100:820-825.
10. Ferri C, Pittoni V, Piccoli A, et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995;80:829-835.
11. Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20:255-268.
12. Ahlborg G, Lindstrom J. Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans. J Appl Physiol. 2002;93:2112-2121.
13. Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 2003;52:1904-1909.
14. Bohm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (London). 2002;102:321-327.
15. Bohm F, Beltran E, Pernow J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J Intern Med. 2005;257:263-271.
16. Cardillo C, Campia U, Kilcoyne CM, et al. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 2002;105:452-456.
17. Iwasa S, Fan J, Shimokama T, et al. Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis. 1999;146:93-100.
18. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
19. Bohm F, Ahlborg G, Johansson BL, et al. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:674-679.
20. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752-756.
21. Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963;88:137-146.
22. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112:666-673.
23. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454.
24. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J-17J.
25. Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233-2240.
26. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelinA-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058.
27. Wedgwood S, McMullan DM, Bekker JM, et al. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res. 2001;89:357-364.
28. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis. 2002;160:297-304.
29. Taner CB, Severson SR, Best PJM, et al. Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia. J Appl Physiol. 2001;90:816-820.
30. Gonon AT, Erbas D, Broijersen A, et al. Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2004;285:H1767-H1774.